Cargando…

Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma

OBJECTIVES: We aimed to develop and validate radiologic scores from [(18)F]FDG PET/CT and MRI to guide individualized induction chemotherapy (IC) for patients with T3N1M0 nasopharyngeal carcinoma (NPC). METHODS: A total of 542 T3N1M0 patients who underwent pretreatment [(18)F]FDG PET/CT and MRI were...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shan-Shan, Wu, Yi-Shan, Pang, Ya-Jun, Xiao, Su-Ming, Zhang, Bao-Yu, Liu, Zhi-Qiao, Chen, En-Ni, Zhang, Xu, OuYang, Pu-Yun, Xie, Fang-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123027/
https://www.ncbi.nlm.nih.gov/pubmed/34989842
http://dx.doi.org/10.1007/s00330-021-08460-1
_version_ 1784711474420121600
author Yang, Shan-Shan
Wu, Yi-Shan
Pang, Ya-Jun
Xiao, Su-Ming
Zhang, Bao-Yu
Liu, Zhi-Qiao
Chen, En-Ni
Zhang, Xu
OuYang, Pu-Yun
Xie, Fang-Yun
author_facet Yang, Shan-Shan
Wu, Yi-Shan
Pang, Ya-Jun
Xiao, Su-Ming
Zhang, Bao-Yu
Liu, Zhi-Qiao
Chen, En-Ni
Zhang, Xu
OuYang, Pu-Yun
Xie, Fang-Yun
author_sort Yang, Shan-Shan
collection PubMed
description OBJECTIVES: We aimed to develop and validate radiologic scores from [(18)F]FDG PET/CT and MRI to guide individualized induction chemotherapy (IC) for patients with T3N1M0 nasopharyngeal carcinoma (NPC). METHODS: A total of 542 T3N1M0 patients who underwent pretreatment [(18)F]FDG PET/CT and MRI were enrolled in the training cohort. A total of 174 patients underwent biopsy of one or more cervical lymph nodes. Failure-free survival (FFS) was the primary endpoint. The radiologic score, which was calculated according to the number of risk factors from the multivariate model, was used for risk stratification. The survival difference of patients undergoing concurrent chemoradiotherapy (CCRT) with or without IC was then compared in risk-stratified subgroups. Another cohort from our prospective clinical trial (N = 353, NCT03003182) was applied for validation. RESULTS: The sensitivity of [(18)F]FDG PET/CT was better than that of MRI (97.7% vs. 87.1%, p < 0.001) for diagnosing histologically proven metastatic cervical lymph nodes. Radiologic lymph node characteristics were independent risk factors for FFS (all p < 0.05). High-risk patients (n = 329) stratified by radiologic score benefited from IC (5-year FFS: IC + CCRT 83.5% vs. CCRT 70.5%; p = 0.0044), while low-risk patients (n = 213) did not. These results were verified again in the validation cohort. CONCLUSIONS: T3N1M0 patients were accurately staged by both [(18)F]FDG PET/CT and MRI. The radiologic score can correctly identify high-risk patients who can gain additional survival benefit from IC and it can be used to guide individualized treatment of T3N1M0 NPC. KEY POINTS: • [ (18) F]FDG PET/CT was more accurate than MRI in diagnosing histologically proven cervical lymph nodes. • Radiologic lymph node characteristics were reliable independent risk factors for FFS in T3N1M0 nasopharyngeal carcinoma patients. • High-risk patients identified by the radiologic score based on [ (18) F]FDG PET/CT and MRI could benefit from the addition of induction chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08460-1.
format Online
Article
Text
id pubmed-9123027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91230272022-05-22 Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma Yang, Shan-Shan Wu, Yi-Shan Pang, Ya-Jun Xiao, Su-Ming Zhang, Bao-Yu Liu, Zhi-Qiao Chen, En-Ni Zhang, Xu OuYang, Pu-Yun Xie, Fang-Yun Eur Radiol Head and Neck OBJECTIVES: We aimed to develop and validate radiologic scores from [(18)F]FDG PET/CT and MRI to guide individualized induction chemotherapy (IC) for patients with T3N1M0 nasopharyngeal carcinoma (NPC). METHODS: A total of 542 T3N1M0 patients who underwent pretreatment [(18)F]FDG PET/CT and MRI were enrolled in the training cohort. A total of 174 patients underwent biopsy of one or more cervical lymph nodes. Failure-free survival (FFS) was the primary endpoint. The radiologic score, which was calculated according to the number of risk factors from the multivariate model, was used for risk stratification. The survival difference of patients undergoing concurrent chemoradiotherapy (CCRT) with or without IC was then compared in risk-stratified subgroups. Another cohort from our prospective clinical trial (N = 353, NCT03003182) was applied for validation. RESULTS: The sensitivity of [(18)F]FDG PET/CT was better than that of MRI (97.7% vs. 87.1%, p < 0.001) for diagnosing histologically proven metastatic cervical lymph nodes. Radiologic lymph node characteristics were independent risk factors for FFS (all p < 0.05). High-risk patients (n = 329) stratified by radiologic score benefited from IC (5-year FFS: IC + CCRT 83.5% vs. CCRT 70.5%; p = 0.0044), while low-risk patients (n = 213) did not. These results were verified again in the validation cohort. CONCLUSIONS: T3N1M0 patients were accurately staged by both [(18)F]FDG PET/CT and MRI. The radiologic score can correctly identify high-risk patients who can gain additional survival benefit from IC and it can be used to guide individualized treatment of T3N1M0 NPC. KEY POINTS: • [ (18) F]FDG PET/CT was more accurate than MRI in diagnosing histologically proven cervical lymph nodes. • Radiologic lymph node characteristics were reliable independent risk factors for FFS in T3N1M0 nasopharyngeal carcinoma patients. • High-risk patients identified by the radiologic score based on [ (18) F]FDG PET/CT and MRI could benefit from the addition of induction chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-08460-1. Springer Berlin Heidelberg 2022-01-06 2022 /pmc/articles/PMC9123027/ /pubmed/34989842 http://dx.doi.org/10.1007/s00330-021-08460-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Head and Neck
Yang, Shan-Shan
Wu, Yi-Shan
Pang, Ya-Jun
Xiao, Su-Ming
Zhang, Bao-Yu
Liu, Zhi-Qiao
Chen, En-Ni
Zhang, Xu
OuYang, Pu-Yun
Xie, Fang-Yun
Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma
title Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma
title_full Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma
title_fullStr Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma
title_full_unstemmed Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma
title_short Development and validation of radiologic scores for guiding individualized induction chemotherapy in T3N1M0 nasopharyngeal carcinoma
title_sort development and validation of radiologic scores for guiding individualized induction chemotherapy in t3n1m0 nasopharyngeal carcinoma
topic Head and Neck
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123027/
https://www.ncbi.nlm.nih.gov/pubmed/34989842
http://dx.doi.org/10.1007/s00330-021-08460-1
work_keys_str_mv AT yangshanshan developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT wuyishan developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT pangyajun developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT xiaosuming developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT zhangbaoyu developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT liuzhiqiao developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT chenenni developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT zhangxu developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT ouyangpuyun developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma
AT xiefangyun developmentandvalidationofradiologicscoresforguidingindividualizedinductionchemotherapyint3n1m0nasopharyngealcarcinoma